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Abstract
Background: A low resting heart rate (HR) is prognostically favourable in healthy individuals and in patients with
left heart disease. In this study we investigated the impact of HR at diagnosis on long-term outcome in patients
with differently classified precapillary pulmonary hypertension (pPH).
Methods: pPH patients diagnosed as pulmonary arterial (PAH) or inoperable chronic thromboembolic pulmonary
hypertension (CTEPH) were registered and regularly followed at our centre Baseline characteristics and events
defined as either death or lung transplantation were noted. The prognostic value of HR was analysed using Kaplan
Meier estimates, live tables and Cox regression.
Results: 206 patients with PAH (148) and inoperable CTEPH (58) were included. The median HR was 82 bpm. pPH
with a HR below 82 bpm had a significantly longer overall event-free survival (2409 vs.1332 days, p = .000). This
advantage was similarly found if PAH and CTEPH were analysed separately. Although a lower HR was associated
with a better hemodynamic and functional class, HR was a strong and independent prognostic marker for
transplant free survival even if corrected for age, sex, hemodynamics and functional status.
Conclusion: We show that resting HR at diagnosis is a strong and independent long-term prognostic marker in
PAH and CTEPH. Whether reducing HR by pharmacological agents would improve outcome in pPH has to be
assessed by future trials with high attention to safety.
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Background
A lower resting heart rate (HR) is prognostically
favourable in healthy individuals or in patients with car-
diovascular disease [1-3]. An increased HR is an inde-
pendent risk factor for cardiovascular and all-cause
mortality in cardiovascular disease and left heart failure
(LHF) [2,4]. In patients with systolic heart failure, the
resting HR-threshold over which an increased mortality
was found, was as low as 70 bpm [1].
The prognostic role of the HR in right sided heart fail-
ure due to precapillary pulmonary hypertension (pPH) is
less clear. Studies have shown that an increased resting
HR was a marker for disease burden and herewith asso-
ciated with an unfavourable prognosis in patients with
pulmonary arterial hypertension (PAH) [5,6]. Compared
to healthy and to patients with left heart disease the cut
off value for an adverse prognosis was higher in PAH
(HR 82 bpm or 87 bpm in untreated and 92 bpm in spe-
cifically treated patients) [5,6]. The pathogenesis under-
lying a relatively increased HR in PAH is not completely
understood. It is thought that the increased right ven-
tricular afterload leads to an impaired right ventricular
stroke volume. This reduced stroke volume will lead
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mainly via sympathetic activation to an increased HR, so
that the cardiac output can be maintained in order to
provide sufficient oxygen to the body, especially during
exercise [7]. The increased HR in PAH might therefore
rather be a consequence of disease burden and not an
independent marker for adverse prognosis [6]. However,
the increased sympathetic response along with the
increased HR may unfavourably affect ventricular re-
modelling [5]. Until now it is not clear whether a lower
HR is an independent prognostic factor in a broader
pPH collective. We therefore aimed to investigate the
prognostic value of the resting HR on long-term out-
come in patients with differently classified pPH includ-
ing PAH and inoperable chronic thromboembolic PH
(CTEPH) [8,9].
Methods
Patients who were diagnosed with pPH by right heart
catheterisation (RHC) and classified in PAH or CTEPH
by WHO [8] gave their written informed consent to have
their data prospectively registered. Quality of life,
NYHA/WHO functional class and 6 minute walk dis-
tance (6MWD) were assessed and registered at baseline
[10]. During the diagnostic RHC, the following para-
meters were recorded as average of two separate mea-
sures during a stable period for at least 15 minutes
recumbent rest: arterial blood pressures, resting HR,
pulmonary artery pressures, right atrial pressure, pul-
monary capillary occlusion pressure and cardiac out-
put by continuous thermodilution. Mean pulmonary
and systemic arterial pressures (mPAP and mAP), sys-
temic and pulmonary vascular resistance (SVR and
PVR) and cardiac index (CI) were calculated. Mixed
venous and arterial blood samples were drawn for
measures of oxygen saturations and partial pressures
of oxygen and carbon dioxide. Patients were there-
after followed at our centre in close collaboration of
specialists and general practitioners. Deaths of any
cause and lung transplantation were defined as
events. In June 2011 records of every single patient
were reviewed for correct event recording and double-
checked with the clinical report. If there were any
doubt about events the general practitioner was con-
tacted to assure life or occurrence of events. Patients
with operable CTEPH who underwent pulmonary em-
bolectomy were excluded from the survival analysis as
the indication to operate is not merely correlated to
disease severity.
The study was performed according to the Declaration
of Helsinki, ICH-GCP as well as all national legal and
regulatory requirements. National and international
guidelines did not require institutional review board ap-
proval because this study was retrieved from our pro-
spective registry.
Statistics
All baseline data is summarized by mean ± standard de-
viation (SD) or medians (quartiles). Baseline variables by
groups were compared using Mann-Witney-U-Test and
Fisher-Test. Differential survival was assessed by Kaplan
Meyer analysis and live tables, significance was tested by
log-rank test and fishers test. Cox regression analysis
was used for multivariate survival analysis. A p < 0.05
was considered significant. SPSS 19.0.0 (SPPS, Inc., Chi-
cago Illinois) and Excel were used.
Results
Patients` characteristics
222 patients with pPH having had baseline evaluation
with diagnostic RHC between January 1998 and June
2011 were included. 16 patients with subsequent pul-
monary endarterectomy were excluded according to the
protocol.
Characteristics of the remaining 206 pPH patients
(130 females, age 55y ±17y) are shown in Table 1. 148
had PAH (55 idiopathic, 32 collagen vascular, 61 other
associated) and 58 had inoperable CTEPH. Patients were
in NYHA II to IV with a markedly reduced baseline
6MWD (386 ±137 m). The mean baseline resting HR
was 82 ±14 bpm, the mPAP was 45 ±18 mmHg and
PVR 775 ±464 dyn*s*m-5. Conventional medical treat-
ment at baseline consisted of diuretics and oral anticoa-
gulation. After baseline evaluation HR assessment, the
following treatments had been started: Endothelin-1 re-
ceptor antagonists (85), Phosphodiesterase inhibitors
(34), inhaled (63) or parenteral Prostanoids (8) and cal-
cium antagonists (37, positive responders to acute vaso-
dilator therapy, mostly switched to other therapies
during follow-up.
During the median follow-up of 37 (18;64) months, 24
patients died (18 PAH and 6 inoperable CTEPH), and 3
received lung transplantation (1 PAH and 2 CTEPH).
Median overall survival was 4.8 years.
Differences between pulmonary arterial and inoperable
chronic thromboembolic pPH
Patients with PAH were significant younger at baseline
compared to CTEPH (51 ±18 vs. 61 ±12 y, p = 0.008)
and had a higher mixed venous oxygen saturation
(SmvO2 61 ±11 vs. 57 ±10, p = 0.014). We found no
other baseline differences and the overall event-free sur-
vival were similar in both classes (median 1776 vs.
1653 days, p = 0.47).
Baseline and outcome difference according to resting
heart rate
Patients characteristic for patients with resting HR below
and above the median of 82 bpm are shown in
Table 2. Patients with higher HR had less favourable
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hemodynamics, i.e. higher mPAP and PVR and lower
SmvO2.
We found a significantly longer event-free survival for
patients with a HR below 82 bpm (log rank p = 0.006,
Figure 1). After 10 years, 61 (60%) patients with a base-
line HR below 82 bpm were still alive compared with 48
(46 %) of patients with a HR ≥82 bpm. Consequently,
the median transplant-free survival was significantly
lower if the baseline HR was ≥82 bpm compared to
<82 bpm (1581 vs. 2660 days, p < 0.0001). This signifi-
cant event-free survival difference persisted even
if PAH and CTEPH were analysed separately (p = 0.027
and p < 0.001). Analysis of the idiopathic and collagen
vascular disease associated PAH subgroups revealed that
a significant survival difference was found up to 8 and
5 years, respectively, but not thereafter due to the small
number of cases at risk.
If, in analogy to left heart failure studies [1,3], lower cut
off levels for the resting HR were taken, patients with
lower resting HR cut offs had more favourable
hemodynamics compared to patients above the cut off,
Figure 2. Thus, for thresholds of 70 or 75 bpm, the mPAP
measures were 40 ±14 and 42 ±13 compared with 49 ±17
and 50 ±17 mmHg (p = 0.002 and .008, respectively); the
calculated PVR was 594 ±402 and 643 ±407 vs. 816 ±453
and 834 ±459 dyn*s*m-5 (p = 0.004 and p = 0.003). Me-
dian survival were 2008 and 1766 vs. 4028 and 3170 days
for cut offs of 70 and 75 bpm (p = 0.087 and p = 0.002),
respectively. The cumulative Kaplan Meyer survival differ-
ences did not reach statistical significance for the cut off
of 70 bpm (log rank p = 0.069) but highly significant for
the cut off of 75 bpm. A relatively high HR cut off of
92 bpm still revealed an advantage for patients with a HR
below this value (p = 0.001).
Multivariate survival analysis
In a multivariate Cox regression model including sex, age,
PVR and HR, the resting HR was the strongest independ-
ent survival predictor (p < 0.0001). Baseline resting HR
remained the strongest independent predictor of sur-
vival even when WHO functional class or the 6MWD
were additionally included in the model (p < 0.0001 and
p = 0.002). Resting HR persisted as strongest independent
predictor even if the PVR was replaced by the cardiac
index (p < 0.0001) or the right atrial pressure (p = .002) in
the multivariate regression model.
Discussion
In this long-time follow up collective of well characterized
patients with PAH and CTEPH we found that a low rest-
ing HR at diagnosis was a strong and independent pre-
dictor of a favourable long-term outcome overall and for
both groups separately. pPH patients with a resting HR
below thresholds of 75 to 82 bpm had a markedly and sig-
nificantly prolonged median survival compared to patients
with higher resting HR. A lower resting HR remained an
independent predictor of favourable outcome even if cor-
rected for demographics, pulmonary hemodynamic, exer-
cise capacity and functional class.
Many epidemiological studies in left heart failure have
shown that a reduction of the HR improves cardiovascular
outcome [1,3], implicating that an increased HR might
not only be a mere compensatory mechanism, but, rather
more, might represent an adverse factor on cardiac
hemodynamics itself. The underlying mechanisms are not
fully elucidated.
One explanation might be that the decreased diastolic
filling time due to a shortened heart cycle does not allow
Table 1 Patients’ baseline characteristics
Numbers (%) Mean ± SD
Total number of patients 206
Female/male 130/76 (63/37)
Age (years) 55 ± 17
Precapillary Pulmonary arterial
hypertension:
-Idiopathic 55 (27)
-Associated to collagen vascular disease 32 (16)
-Other associated PAH 61 (30)
-Chronic thromboembolic PH not
eligible for surgery
58 (28)
NYHA functional class I/II/III/IV 1/37/104/62 (1/18/51/30)*
BMI (kg/m2) 25 ±5
Mean resting heart rate (bpm) 82 ±14
Mean arterial pressure (mmHg) † 90 ±14
Mean pulmonary arterial
pressure (mmHg) †
45 ±18
Pulmonary vascular resistance
(dyn*sec*m-5) †
775 ±464
Cardiac index (l/min/m2) † 2.4 ±0.8
Right atrial pressure (mmHg) † 9 ±6
NT-pro-BNP (ng/l, < 130) 1826 ±2269
6 minute walking distance (m) 386 ±137
Mean follow up (months) 45 ±35
Percentage survivors at year 1, 3, 5, 7, 9 84/67/57/55/53
Medication after baseline:
-Calcium antagonist 37 (18)
-Prostacyclin analogues (by inhalation) 63 (31)
-Prostacyclin analogues (parenteral) 8 (4)
-Endothelin-1 receptor antagonist 96 (47)
-Phosphodiesterase inhibitor 34 (17)
* For two patients data were not registered, † measured by right heart catheter;
Data is given as number (%) or mean ± SD. NYHA: New York Heart Association,
WHO: World health organization, BMI: Body mass index, NT-pro-BNP: NT-pro
brain natriuretic peptide.
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Table 2 Difference in baseline characteristics by median resting heart rate
< 82 bpm Numbers (%) Mean ± SD > 82 bpm Numbers (%) Mean ± SD p
Total number of patients 101 105 0.780
Female/male 60/41 (59/41) 70/35 (67/33) 0.64/0.5
Age (years) 57 ±17 54 ±16 0.158
Idiopathic 24 (24) 31 (30) 0.345
Connective tissue disease 15 (15) 17 (16) 0.724
Other PAH 29 (29) 32 (31) 0.701
Chronic thromboembolic PH not
eligible for surgery
33 (33) 25 (24) 0.294
WHO functional class I/II/III/IV 0/20/54/25 (20/54/25) 1/17/50/37 (16/48/35) 0.59/0.71/0.30
BMI (kg/m2) 25 ±5 25 ±6 0.545
Resting Heart Rate (bpm) 71 ±7 93 ±9 <0.001**
Mean arterial pressure (mmHg)† 88 ±14 91 ±14 0.116
Mean pulmonary arterial
pressure (mmHg) †
42 ±16 48 ±19 0.04*
Pulmonary vascular
resistance (dyn*sec*m-5) †
661 ±396 884 ±499 0.01*
Cardiac index (l/min/m2) † 2.5 ±0.8 2.2 ±0.8 0.18
Right atrial pressure (mmHg) † 7 ±5 11 ±7 <0.001**
NT-pro-BNP (ng/l, < 130) 1593 ±2079 2043 ±2429 0.283
6 minute walking distance (m) 409 ±141 366 ±131 0.11
Mean follow up (days) 1530 1179 0.15
Percentage survivors at year 1, 3, 5, 7, 9 93/78/68/64/62 77/57/49/48/47 0.40/0.18/0.19/0.23/0.28
Median survival (years) 6.6 3.7 <0.001**
* Significant,** highly significant † measured by right heart catheter;
Data is given as number (%) or mean ± SD. NYHA: New York Heart Association, WHO: World health organization, BMI: Body mass index, NT-pro-BNP: NT-pro brain
natriuretic peptide.
Figure 1 10 year transplant free survival is shown for 206
patients with precapillary pulmonary hypertension. Red line:
patients with a baseline resting heart rate below 82 bpm. Blue line:
patients with a baseline resting heart rate above 82 bpm, p = 0.004.
Figure 2 10 year transplant free survival is shown for 206
patients with precapillary pulmonary hypertension. Red line:
patients with a baseline resting heart rate below 75 bpm. Blue line:
patients with a baseline resting heart rate above 75 bpm, p = 0.007.
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sufficient myocardial perfusion to supply adequate oxygen
to the diseased heart. Another reason might be that the
augmented sympathetic activity leading to an increased
HR is overshooting and, in turn, has adverse effects itself.
The fact that not only sympathetic blockade by beta re-
ceptor blockers, but also mere HR reduction by Ion chan-
nel modification, result in a better outcome in patients
with left heart failure points against the hypothesis of a
single sympathetic adverse effect responsible for higher
HR along with unfavourable outcomes [11,12].
In this study we could demonstrate that a lower resting
HR is not only a favourable prognostic factor in patients
with left heart failure, but also in patients with right heart
failure due to differently classified pPH. Although patients
with a lower resting HR had a better hemodynamic pro-
file, functional class and relatively preserved exercise cap-
acity, the fact that the resting HR remained an
independent prognostic factor even if corrected for age,
sex, pulmonary vascular resistance, exercise and func-
tional capacities underscores that resting HR not only
reflects the degree of disease burden but represents an in-
dependent predictor by itself in patients with pPH.
Although several studies linked a lower resting HR to
longevity in healthy individuals and especially in patients
with left heart disease [1,2,13,14], the assessment of HR
thresholds, at which risk may increase, has not been the
focus of studies until recent publications [1,15]. More-
over, the prognostic value of HR in major groups such
as heart failure with preserved ejection fraction was only
recently addressed [15]. These studies in LHF showed
that a resting HR threshold as low as 70 bpm was prog-
nostically discriminative. In the present study including
patients with pPH, we tested several resting HR cut off
points based on the median HR and in comparison with
previously published cohorts of patients with left heart
failure, where a cut off of 70 bpm was found [1], and a
published cohort of idiopathic PAH, were a HR thresh-
olds of 80 bpm was assessed [6]. In analogy to the later
cohort, we found that a baseline resting HR above
82 bpm, the median in our cohort, was independently
associated with increased mortality. We can therefore
extend these published results to a broader and clinical
relevant and realistic pPH population including asso-
ciated PAH and CTEPH. Reducing the HR threshold to
75 bpm even better identified patients with a more
favourable prognosis. A further threshold decrease to
70 bpm in analogy to published data in left heart disease,
did not significantly differentiate the prognosis, most
probably due to the small sample size, since only few
patients in our cohort had resting HR below 70 bpm.
Recent guidelines do not include HR as prognostic
marker, as the prognostic significance of HR in right
heart failure due to pulmonary vascular disease had not
been sufficiently studied [9,16]. Our data can fill this cap
by showing that resting HR is an independent prognostic
marker irrespective of demographics, hemodynamics
and functional class. We herewith advocate that HR
should be integrated in the clinical management, guide-
lines and trials including pPH patients.
At physiological pressures, the thin-walled, highly
compliant RV can accommodate with high volumes (pre-
load-dependency) [17]. However, in pPH the markedly
increased RV afterload stresses the RV and results in in-
efficient work, especially during exercise. The capability
to increase HR during exercise is therefore thought to
be a key factor to maintain cardiac output. Therefore,
most experts agreed for decades that agents which re-
duce HR and remove the body’s possibility to react with
a chronotropic response towards the increased RV after-
load are contraindicated in pPH [18,19]. In addition, the
most frequently used agents to control HR, the beta ad-
renergic receptor blocker, could induce pulmonary vaso-
constriction. However, several recent studies indicate
that the beta-adrenergic system is over stimulated in pPH
and this overstimulation may lead to a maladaptive RV re-
modelling as found in pPH [18,19]. Furthermore, supraven-
tricular tachyarrhythmias are frequently found in pPH and
associated with increased morbidity [20]. Beta adrenergic
receptor blocker therapy have been shown to reduce
mortality by about a third in left heart disease regard-
less of disease severity [21,22]. Reducing HR in left heart
disease by this therapy reverses the maladaptive cardiac
remodelling (at least partially), improves cardiac function
and prevents arrhythmias [23]. However, these agents are
either not mentioned in pPH guidelines or their use dis-
couraged for fear of detrimental effects on hemodynamics
due to the reduced chronotropic response, especially dur-
ing exercise [16,24,25]. It may well be that these negative
short-term effects of beta adrenergic blockage could be
overcome by a reversal of the maladaptive cardiac remod-
elling, as suggested by data from a pPH animal model
[19]. Theoretically, a HR decrease could also improve RV
function by prolonging the relative duration of diastolic
filling. This would allow a better coronary perfusion and
oxygen delivery to the hypertrophied and often hypoper-
fused myocardium and may lead to an improved RV sys-
tolic function. Whether a treatment strategy aimed at
slowing resting HR and reducing the increased beta-
adrenergic response in pPH would be beneficial in pPH is
still unclear. The results of our long-term study in pPH
and other studies in idiopathic PAH showed that a
reduced HR is prognostically important. Whether the
medicamentous reduction of HR in pPH would be benefi-
cial in pPH remains to be elucidated by future, well
designed trial with special attention to the safety of such
agents.
Our study is relatively small, however, pPH is a rare
disease and we can provide robust long-term flow-up
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data in a thoroughly investigated and well followed pPH
collective. Resting HR was carefully obtain after at least
10 minutes of rest with stable continuous hemodynamic
curves on the monitor over at least 10 minutes.
Conclusions
In summary, our data show for the first time that base-
line resting heart rate is a strong and independent long-
term prognostic factor in a broad pPH collective includ-
ing PAH and CTEPH. Whether reducing HR by
pharmacological agents would improve outcome in pPH
has to be assessed by future designed trials with high at-
tention to safety.
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